Duvie S

Duvie S is a fixed-dose combination (FDC) pharmaceutical product developed by Chong Kun Dang Pharmaceutical for the management of type 2 diabetes mellitus. It combines two glucose-lowering agents with complementary mechanisms of action: lobeglitazone and sitagliptin. Lobeglitazone is a thiazolidinedione (TZD) that acts as a selective agonist for the peroxisome proliferator-activated receptor gamma (PPAR-gamma), which enhances insulin sensitivity in adipose tissue, muscle, and the liver. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. The combination is designed to provide superior glycemic control compared to monotherapy by addressing both insulin resistance and pancreatic beta-cell dysfunction.

Brand names

Duvie S

Other names

Lobeglitazone + SitagliptinLobeglitazone/SitagliptinCKD-501 + D759